Changes in global quality of life after treatment with immune checkpoint inhibitors in patients receiving different treatment regimens for advanced stage lung cancer in the Netherlands: a 2015–2021 cohort study
The changes in gQoL over time among patients with advanced-stage lung cancer may vary by treatment regimens based on drug intensity, line and intent of treatment, which will help clinicians and patients understand the potential dynamic of treatments on QoL. It may further influence treatment decisions and patient management strategies, reflecting the practical implications of different treatment regimens.
Authors
- Bernard Rachet (ORCID: https://orcid.org/0000-0001-5837-7773)
- Manuela Quaresma (ORCID: https://orcid.org/0000-0002-5290-279X)
- Erick Suazo-Zepeda (ORCID: https://orcid.org/0000-0003-1518-7405)
- Petra C. Vinke (ORCID: https://orcid.org/0000-0002-6603-1964)
- Willemijn J Maas (ORCID: https://orcid.org/0000-0002-0792-7090)
- Ananya Malhotra (ORCID: https://orcid.org/0000-0002-0691-0705)
- Geertruida H. de Bock (ORCID: https://orcid.org/0000-0003-3104-4471)
- T. Jeroen N. Hiltermann (ORCID: https://orcid.org/0000-0002-0665-2160)
- Clémence Leyrat (ORCID: https://orcid.org/0000-0002-4097-4577)
Institutions
- University Medical Center Groningen (NL)
- University of Groningen (NL)
- London School of Hygiene & Tropical Medicine (GB)
Publication Details
- Journal
- BMJ Open
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1136/bmjopen-2024-098062
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Cancer Research UK
- European Commission
- Consejo Nacional de Ciencia y Tecnología
- Medical Research Council